Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation

被引：14
|
作者：
Restelli, Valentina [1 ]
Vagni, Micaela [1 ]
Arribas, Alberto J. [2 ]
Bertoni, Francesco [2 ,3 ]
Damia, Giovanna [1 ]
Carrassa, Laura [1 ]
机构：
[1] IRCCS, Ist Ric Farmacol Mario Negri, Dept Oncol, Lab Mol Pharmacol, Milan, Italy
[2] IOR Inst Oncol Res, Lymphoma & Genom Res Program, Bellinzona, Switzerland
[3] IOSI Oncol Inst Southern Switzerland, Bellinzona, Switzerland
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷 / 01期
关键词：
diffuse large B cell lymphoma; CHK1; WEE1; MYC; combined targeted therapy; PHASE; COMBINATION; CANCER;
D O I：
10.1111/bjh.14506
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：129 / 133
页数：5
相关论文
共 50 条
  • [31] Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
    Gry Irene Magnussen
    Elisabeth Emilsen
    Karianne Giller Fleten
    Birgit Engesæter
    Viola Nähse-Kumpf
    Roar Fjær
    Ana Slipicevic
    Vivi Ann Flørenes
    BMC Cancer, 15
  • [32] ATR/CHK1/WEE1 DEPENDENCY IN SRSF2-MUTATED MDS/AML
    Eldfors, Samuli
    Rai, Sumit
    Sharma, Vineet
    Hossan, Tareq
    Cabrera, Claudia
    Bertino, Amy
    Gilbert, Angelique
    Walter, Matthew
    Porkka, Kimmo
    Graubert, Timothy
    EXPERIMENTAL HEMATOLOGY, 2024, 137
  • [33] Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
    Magnussen, Gry Irene
    Emilsen, Elisabeth
    Fleten, Karianne Giller
    Engesaeter, Birgit
    Nahse-Kumpf, Viola
    Fjaer, Roar
    Slipicevic, Ana
    Florenes, Vivi Ann
    BMC CANCER, 2015, 15
  • [34] Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells
    Mak, Joyce P. Y.
    Man, Wing Yu
    Chow, Jeremy P. H.
    Ma, Hoi Tang
    Poon, Randy Y. C.
    ONCOTARGET, 2015, 6 (25) : 21074 - 21084
  • [35] Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation
    Zhao, Xiaoliang
    Kim, In-Kyu
    Kallakury, Bhaskar
    Chahine, Joeffrey J.
    Iwama, Eiji
    Pierobon, Mariaelena
    Petricoin, Emanuel
    McCutcheon, Justine N.
    Zhang, Yu-Wen
    Umemura, Shigeki
    Chen, Vincent
    Wang, Changli
    Giaccone, Giuseppe
    MOLECULAR ONCOLOGY, 2021, 15 (04) : 1130 - 1145
  • [36] Chk1 and WEE1 Inhibition Combine Synergistically and Represent a Novel Non-cytotoxic Combination in Acute Myeloid Leukemia
    Tibes, Raoul
    Chaudhuri, Leena
    Vincelette, Nicole D.
    Kohl, Brian D.
    Naylor, Ryan M.
    Flatten, Karen S.
    Peterson, Kevin L.
    McNally, Amanda
    Gojo, Ivana
    Karp, Judith E.
    Mesa, Ruben A.
    Sproat, Lisa O.
    Bogenberger, James M.
    Kaufmann, Scott H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S127 - S128
  • [37] EVALUATION OF BBB PERMEABLE WEE1 AND CHK1 INHIBITORS IN COMBINATION WITH STANDARD OF CARE FOR THE TREATMENT OF GLIOBLASTOMA
    Scholefield, E. L.
    Gomez-Roman, N.
    NEURO-ONCOLOGY, 2024, 26 : V72 - V72
  • [38] A siRNA high-throughput screening identified Wee1 as determinant of Chk1 inhibitor sensitivity
    Carrassa, Laura
    Chila, Rosaria
    Lupi, Monica
    Ricci, Francesca
    Mazzoletti, Marco
    Celenza, Cinzia
    Broggini, Massimo
    Damia, Giovanna
    CANCER RESEARCH, 2012, 72
  • [39] The critical role of CDK2 activation in determining the differential sensitivity of cell lines to Chk1 and Wee1 inhibitors
    Sakurikar, Nandini
    Thompson, Ruth
    Montano, Ryan
    Eastman, Alan
    CANCER RESEARCH, 2015, 75
  • [40] Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer
    Gupta, Nitasha
    Huang, Tzu-Ting
    Horibata, Sachi
    Lee, Jung-Min
    PHARMACOLOGICAL RESEARCH, 2022, 178
12345